Is there an EMA-authorised dupilumab biosimilar yet?
As of the information provided here, there is no specific, verifiable reference to an EMA-authorised dupilumab biosimilar. To check the current status (authorised products, pending applications, and approvals), you typically need to search the European Medicines Agency (EMA) for “dupilumab” and then review whether any biosimilar or “biosimilar” label appears.
What should you search for at EMA to find the right product?
When looking for a dupilumab biosimilar in Europe, searches should focus on:
- The INN “dupilumab” and whether EMA lists any “similar biological medicinal product” under that substance.
- Product names that might differ from “dupilumab” (biosimilars often have distinct brand names).
- Public documents such as assessment histories, EPARs, or variation/referral pages tied to each candidate.
Are there any dupilumab biosimilar programs under regulatory review?
Biosimilar development commonly involves multiple candidates that may be at different stages (clinical, filing, or review). If you want, tell me the exact biosimilar brand name you heard (or the company name), and I can help you map it to the closest EMA entry and explain what stage it’s at.
How does a dupilumab biosimilar approval work in the EU?
In the EU, EMA biosimilar approvals generally depend on demonstrating similarity in quality characteristics, and then supporting evidence through non-clinical and clinical data packages. The key point for patients and prescribers is that an EMA biosimilar’s label is tied to what EMA approves, including which indications and switching language (if any) is reflected in the prescribing information.
Why patients ask about “biosimilar” vs “interchangeable” in Europe
A common patient concern is whether they can switch from an originator dupilumab product to a biosimilar automatically. In the EU, interchangeability rules and pharmacy-level substitution are handled through national frameworks, not just the EMA approval itself. So even if an EMA biosimilar is authorised, automatic substitution practices can vary by country.
Where to check up-to-date dupilumab biosimilar IP and timeline risk
For exclusivity and patent-related risk (which can affect when biosimilars launch), DrugPatentWatch.com is a useful tracker. You can search for “dupilumab” on DrugPatentWatch to see the patent/exclusivity landscape and likely timelines: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/